NCT00672191View on ClinicalTrials.gov

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

November 30, 2011

Conditions
HIV Infections
Interventions
BIOLOGICAL

AGS-004

HIV-1 Immune Therapy

Trial Locations (12)

19102

Practice Comprehensive Care Practice Div of Onfectious Disease & HIV Med, Philadelphia

T2R0X7

Southern Alberta Clinic, Calgary

V6Z1Y6

Providence Health Care Society / The University of British Columbia / BC Centre for Excellence in HIV/AIDS, Vancouver

L7R3X5

Hamilton Health Sciences - McMaster University Medical Centre, Hamilton

K1H8L6

The Ottawa Hospital, Ottawa

M4N3M5

Sunnybrook Health Sciences Center, Toronto

M5B 1L6

Maple Leaf Clinic, Toronto

M5G2C4

UHN, Toronto

H2L4P9

Clinique medicale l'Actuel, Montreal

H2L5B1

Clinique Medical du Quartier Latin, Montreal

H2X 2P4

Montreal Chest Institute, Montreal

Unknown

CHUM, Montreal

Sponsors

Lead Sponsor

Argos Therapeutics
All Listed Sponsors
lead

Argos Therapeutics

INDUSTRY

NCT00672191 - Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV | Biotech Hunter | Biotech Hunter